Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

2003 • 1,933 citations

Drug-Induced Hepatotoxicity

2003 • 1,591 citations

Oxidative stress: From basic research to clinical application

1991 • 1,302 citations

Drug Metabolism and Variability among Patients in Drug Response

2005 • 1,138 citations

Criteria of drug-induced liver disorders

1990 • 1,071 citations

An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy

2006 • 1,062 citations

Drug-Related Hepatotoxicity

2006 • 1,049 citations

The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism

2002 • 885 citations

Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis

2003 • 816 citations

Tuberculosis

2003 • 700 citations

Treatment for tuberculosis, guidelines for national programmes

1994 • 636 citations

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

1992 • 536 citations

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998

1998 • 532 citations

Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis

1976 • 513 citations

Treatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection

1991 • 486 citations

Hepatotoxicity Associated With Isoniazid Preventive Therapy

1999 • 469 citations

Toxic Hepatitis with Isoniazid and Rifampin

1991 • 438 citations

Therapeutic Drug Monitoring in the Treatment of Tuberculosis

2002 • 437 citations

Effect of age and gender on the activity of human hepatic CYP3A

1992 • 425 citations

Polymorphism of theN-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

2002 • 423 citations

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

2003 • 414 citations

Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis

1996 • 380 citations

Isoniazid-Associated Hepatitis in 114 Patients

1975 • 372 citations

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy

2002 • 370 citations

Idiosyncratic drug reactions: the reactive metabolite syndromes

2000 • 329 citations

Evaluation of Clinical and Immunogenetic Risk Factors for the Development of Hepatotoxicity during Antituberculosis Treatment

2002 • 324 citations

Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management

2005 • 317 citations

Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.

1989 • 303 citations

Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

1975 • 301 citations

Drug-Induced Hepatotoxicity

1995 • 291 citations

Antituberculosis Drug–induced Hepatotoxicity

1998 • 285 citations

An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment

2004 • 280 citations

The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal And Antiviral Drugs

1997 • 277 citations

Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection

2005 • 251 citations

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

2000 • 250 citations

Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected Subjects

2005 • 244 citations

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial

2004 • 243 citations

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

1996 • 240 citations

Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat

1976 • 228 citations

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

2000 • 226 citations

Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.

2001 • 220 citations

Management of tuberculosis : a guide for low income countries

2000 • 209 citations

Clinical Pharmacokinetics of the Antituberculosis Drugs

1984 • 206 citations

Influence of Diet and Nutritional Status on Drug Metabolism

1996 • 204 citations

Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

2002 • 202 citations

Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

2006 • 197 citations

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

1977 • 193 citations

Should We Use N -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?

2005 • 192 citations

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.

1997 • 191 citations

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

2006 • 187 citations

Pharmacokinetics of isoniazid metabolism in man

1976 • 183 citations

Increased risk of antituberculosis drug‐induced hepatotoxicity in individuals with glutathione S‐transferase M1 ‘null’ mutation

2001 • 182 citations

Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A

2001 • 176 citations

Hepatic side-effects of antibiotics

1994 • 173 citations

Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection

2006 • 167 citations

Liver injury during antituberculosis treatment: An 11-year study

1996 • 160 citations

Low Antituberculosis Drug Concentrations in Patients with AIDS

1996 • 156 citations

Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment

1996 • 155 citations

Isoniazid – and rifampicin–induced oxidative hepatic injury – protection by N–acetylcysteine

2000 • 153 citations

Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease

2004 • 148 citations

Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

2001 • 143 citations

Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent Tuberculosis

2003 • 138 citations

Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome

1993 • 136 citations

Adverse reactions to rifampicin in antituberculosis regimens

1977 • 136 citations

Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents.

1997 • 136 citations

Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin

2005 • 136 citations

Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment

2004 • 123 citations

The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.

2004 • 122 citations

Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.

1986 • 115 citations

Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.

2002 • 112 citations

Study of Oxidative-Stress in Isoniazid-Rifampicin Induced Hepatic Injury in Young Rats

1997 • 112 citations

High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis: Table. 1—

2005 • 106 citations

Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits

1996 • 103 citations

Effect of rifampicin on liver function in man

1972 • 102 citations

Tuberculosis management in EuropeRecommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.

1999 • 99 citations

Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal.

2003 • 97 citations

Plasma Hydrazine Concentrations in Man after Isoniazid and Hydralazine Administration

1985 • 97 citations

Absorption, metabolism and excretion of pyrazinamide in man

1969 • 92 citations

Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.

2005 • 91 citations

Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis

2003 • 83 citations

Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.

2002 • 75 citations

Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.

1981 • 74 citations

A model of isoniazid-induced hepatotoxicity in rabbits

1995 • 72 citations

Inhibitory Effect of Antituberculosis Drugs on Human Cytochrome P450-Mediated Activities

2004 • 69 citations

Severe hepatotoxicity due to anti-tuberculosis drugs in Spain.

2005 • 67 citations

Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype

1986 • 66 citations

Hepatotoxicity of Rifampin and Pyrazinamide in the Treatment of Latent Tuberculosis Infection in HIV-Infected Persons: Is It Different Than in HIV-Uninfected Persons?

2004 • 64 citations

Tuberculosis management in Europe Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region.

1999 • 61 citations

Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment.

2007 • 60 citations

Tuberculosis drug development pipeline: progress and hope

2006 • 57 citations

Study of oxidative stress in isoniazid-induced hepatic injury in young rats with and without protein-energy malnutrition

1996 • 56 citations

Studies on hydrazine hepatotoxicity. 1. Pathological findings

1982 • 52 citations

Induction of oxidative stress in antitubercular drug-induced hepatotoxicity.

2001 • 51 citations

Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment

2005 • 49 citations

Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis

1994 • 48 citations

Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/ CDC Recommendations—United States, 2001

2001 • 47 citations

Studies on hydrazine hepatotoxicity. 2. Biochemical findings

1982 • 45 citations

Interaction of rifampicin with other drugs

1980 • 42 citations

Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?

2006 • 40 citations

Is Isoniazid - Hepatotoxicity Induced by the Metabolite, Hydrazine?

1983 • 40 citations

Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells

1997 • 39 citations

Fatal and Severe Hepatitis Associated With Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection—New York and Georgia, 2000

2001 • 38 citations

Observations on the reduction of the renal elimination of orate in man caused by the administration of pyrazinamide

1976 • 38 citations

Spin trapping of a free radical intermediate formed during microsomal metabolism of hydrazine

1985 • 36 citations

THE PATHOLOGICAL ANATOMY OF HYDRAZINE POISONING

1908 • 36 citations

Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo

1994 • 36 citations

Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats.

2001 • 32 citations

The role of oxygen free radicals in isoniazid-induced hepatotoxicity

1998 • 29 citations

Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy

2002 • 29 citations

Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients

1992 • 28 citations

Levofloxacin Treatment of Active Tuberculosis and the Risk of Adverse Events

2005 • 27 citations

In vitromicrosomal metabolism of hydrazine

1995 • 18 citations

Effect of acute and repeated exposure to low doses of hydrazine on hepatic microsomal enzymes and biochemical parameters in vivo

1994 • 18 citations

Metabolic activation of hydrazines.

1981 • 17 citations

The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450

1980 • 15 citations

SURGICAL LECTURES

1824 • 6 citations